New Phase III data on gefurulimab highlight potential as a self-administered treatment option; real-world evidence reinforces clinical benefits of Ultomiris and Soliris
Novartis India has reported total income of Rs. 99.73 crore during the period ended September 30, 2025
Sotyktu continues to demonstrate consistent efficacy and safety across rheumatic conditions
Key secondary endpoints also demonstrated statistically significant and clinically meaningful benefits with Gazyva
New AI capabilities will help scientists identify, optimize, and validate new molecules. Additional applications include manufacturing, medical imaging, and enterprise AI agents
Allergan Aesthetics reaffirms commitment to empowering girls through STEM mentorship and education initiatives
Results demonstrate favorable safety profile and clinically meaningful improvements in patients with non-ischemic heart failure
Advancing toward Phase 2a evaluation in chemotherapy-related pain, a condition with no approved treatments and potential for FDA Fast Track designation
Medherant’s testosterone TEPI Patch could become the first-in-class testosterone patch developed specifically for women
Subscribe To Our Newsletter & Stay Updated
